Chimerix (CMRX) Stock Price, News & Analysis

Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $8.54 to $8.54
• 50-Day Range: $8.54 to $8.54
• 52-Week Range: $0.75 to $8.55
• Volume: N/A
• Average Volume: 2.94 million shs
• Market Capitalization: $801.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.53
• Consensus Rating: Hold

Chimerix Stock Analysis - MarketRank™

Chimerix scored higher than 14% of companies evaluated by MarketBeat, and ranked 894th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Chimerix has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Chimerix is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Chimerix has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Chimerix are expected to grow in the coming year, from ($0.99) to ($0.85) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chimerix is -9.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chimerix has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CMRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Chimerix does not currently pay a dividend.

Dividend Growth

Chimerix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.49

Short Interest

There is no current short interest data available for CMRX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for CMRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chimerix insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CMRX Stock Analysis - Frequently Asked Questions

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) announced its earnings results on Friday, March, 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.31 million.

What other stocks do shareholders of Chimerix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD), Pfizer (PFE) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 3/21/2025
• Today: 10/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CMRX
• CIK: 1117480
• Web: www.chimerix.com
• Phone: (919) 806-1074
• Fax: 919-806-1146
• Employees: 90
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Chimerix: $8.53
• High Price Target: $8.55
• Low Price Target: $8.50
• Potential Upside/Downside: -0.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.10 million
• Net Margins: N/A
• Pretax Margin: -52,574.85%
• Return on Equity: -50.78%
• Return on Assets: -44.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.33
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $212 thousand
• Price / Sales: 3,778.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.17 per share
• Price / Book: 3.94

Miscellaneous

• Outstanding Shares: 93,804,000
• Free Float: 78,154,000
• Market Cap: $801.09 million
• Optionable: Optionable
• Beta: -0.17